

## RECENT ADVANCES IN PHARMACEUTICS: NOVEL DRUG DELIVERY SYSTEMS AND EMERGING TECHNOLOGIES

L. MATSYAGIRI

Associate Professor, Department of Pharmaceutics, Omega College of Pharmacy (A), Edulabad, Ghatkesar, Hyderabad, Telangana, India - 501 301.

\*Corresponding Author

Dr. L. Matsyagiri

Article History: Received: 26 Jan 2026, Revised: 11 Mar 2026, Accepted: 14 Apr 2026

**Abstract:** Pharmaceutics is a rapidly evolving discipline that focuses on the design, formulation, and delivery of therapeutic agents to achieve optimal therapeutic outcomes. Conventional drug delivery systems, although widely used, often suffer from limitations such as poor bioavailability, nonspecific distribution, rapid drug degradation, and systemic toxicity. These challenges have driven significant advancements in modern pharmaceutics, particularly in the development of novel drug delivery systems (NDDS) and advanced pharmaceutical technologies. Recent innovations in nanotechnology, biomaterials, polymer science, and biotechnology have revolutionized the way drugs are formulated and delivered in the human body. Nanotechnology-based drug delivery systems such as liposomes, polymeric nanoparticles, dendrimers, and micelles have demonstrated significant improvements in drug solubility, stability, and targeted delivery. These systems allow controlled release of drugs at specific sites, thereby enhancing therapeutic efficacy while minimizing adverse effects. Additionally, sustained and controlled release formulations have improved patient compliance by reducing dosing frequency and maintaining stable plasma drug concentrations. Emerging technologies such as stimuli-responsive drug delivery systems, 3D-printed pharmaceuticals, and biopharmaceutical innovations including monoclonal antibodies, gene therapy, and mRNA-based therapeutics have further expanded the scope of pharmaceutics. These advancements have enabled personalized medicine approaches and precision drug delivery strategies. Despite these advancements, challenges such as scalability, regulatory approval, toxicity concerns, and manufacturing complexity remain significant barriers. However, ongoing research in nanomedicine, smart drug delivery systems, and computational pharmaceutics is expected to overcome these limitations. This review highlights recent developments, applications, challenges, and future perspectives in modern pharmaceutics and drug delivery science.

**Keywords:** Pharmaceutics; Drug Delivery Systems; Nanotechnology; Controlled Release; Targeted Therapy; Biopharmaceuticals.

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License.

Copyright © 2026 Author(s) retains the copyright of this article.



## I. INTRODUCTION

Pharmaceutics is a core branch of pharmaceutical sciences concerned with transforming active pharmaceutical ingredients (APIs) into safe, effective, and stable dosage forms suitable for administration to patients. The primary objective of pharmaceutics is to ensure that drugs reach their intended site of action at appropriate concentrations and durations to produce optimal therapeutic effects.

Traditional dosage forms such as tablets, capsules, suspensions, and injections have been widely used for decades. However, these conventional systems often exhibit several limitations, including poor aqueous solubility, low bioavailability, rapid metabolism, and nonspecific drug distribution. These limitations can lead to reduced therapeutic efficacy and increased systemic side effects.

To overcome these challenges, researchers have developed advanced drug delivery systems that focus on improving drug targeting, controlling release kinetics, and enhancing drug stability. The evolution of pharmaceutics has been strongly influenced by interdisciplinary scientific fields such as materials science, nanotechnology, biotechnology, and polymer chemistry [1].

Modern pharmaceutics is no longer limited to simple formulation science but has evolved into a highly sophisticated discipline integrating biological understanding with engineering principles. The emergence of nanotechnology and smart materials has enabled the development of highly specialized drug carriers capable of responding to physiological conditions within the body [2].

Furthermore, increasing emphasis on personalized medicine has driven the need for patient-specific drug

delivery systems that can adapt dosage and release profiles based on individual biological variability. This shift represents a major transformation from conventional “one-size-fits-all” approaches to precision-based therapeutic strategies [3].

## 2. EVOLUTION OF DRUG DELIVERY SYSTEMS

The evolution of drug delivery systems can be categorized into three major phases:

### 1. Conventional Drug Delivery Systems

These include immediate-release formulations such as tablets and capsules, which release drugs rapidly after administration. Although effective for many conditions, they often require frequent dosing and may cause fluctuations in drug concentration.

### 2. Controlled and Sustained Release Systems

These systems were developed to maintain drug concentration within the therapeutic window for extended periods. They reduce dosing frequency and improve patient compliance.

### 3. Advanced Targeted and Smart Drug Delivery Systems

These represent the latest generation of drug delivery technologies, incorporating nanotechnology, biomaterials, and stimuli-responsive systems for site-specific drug release.

The transition between these stages reflects the continuous effort to improve therapeutic efficiency, reduce side effects, and enhance patient outcomes [4].

## 3. FUNDAMENTALS OF MODERN DRUG DELIVERY

Modern drug delivery systems are designed based on several key principles:

- **Bioavailability enhancement**
- **Controlled pharmacokinetics**
- **Target-specific delivery**
- **Minimization of toxicity**
- **Improved patient compliance**

Drug delivery efficiency depends on multiple factors such as drug physicochemical properties, formulation design, route of administration, and biological barriers. Biological barriers such as the gastrointestinal tract, blood-brain barrier, and cellular membranes significantly influence drug absorption and distribution. Advanced drug delivery systems are engineered to overcome these barriers effectively.

## 4. INTRODUCTION TO NANOTECHNOLOGY IN PHARMACEUTICS

Nanotechnology has emerged as one of the most revolutionary advancements in pharmaceuticals. It involves the design and application of materials at the nanoscale (1–100 nm) for drug delivery purposes.

Nanocarriers enhance drug delivery by improving solubility, stability, and targeting efficiency. Due to their small size, nanoparticles can penetrate biological

barriers and deliver drugs directly to target cells or tissues.

Nanotechnology has enabled significant progress in cancer therapy, infectious disease treatment, and neurological disorder management.

## 5. NANOTECHNOLOGY-BASED DRUG DELIVERY SYSTEMS

Nanotechnology has fundamentally transformed pharmaceuticals by enabling the design of drug carriers at the nanoscale that can improve solubility, stability, bioavailability, and targeted delivery. Nanocarriers offer a major advantage over conventional dosage forms due to their ability to penetrate biological barriers and deliver drugs directly to diseased tissues.

The key mechanism behind nanocarrier efficiency is their high surface-area-to-volume ratio, which enhances drug loading capacity and interaction with biological membranes. Additionally, surface modification of nanoparticles allows ligand-based targeting, improving specificity toward diseased cells such as cancer tissues.

Nanomedicine is now widely applied in oncology, infectious diseases, cardiovascular disorders, and neurological conditions [4].

### 5.1 Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate hydrophilic drugs in their aqueous core and hydrophobic drugs within the lipid bilayer. They are among the most widely studied drug delivery systems in pharmaceuticals.

Liposomes enhance drug stability and reduce toxicity by altering pharmacokinetics and biodistribution. PEGylated liposomes further improve circulation time by avoiding rapid clearance by the reticuloendothelial system.

Clinically approved liposomal formulations are used in anticancer therapy and antifungal treatments, demonstrating their translational success.

### 5.2 Polymeric Nanoparticles

Polymeric nanoparticles are solid colloidal particles made from biodegradable polymers such as PLGA, chitosan, and alginate. These systems provide controlled and sustained drug release by gradual polymer degradation.

They are particularly useful in targeted cancer therapy, gene delivery, and vaccine development. Surface functionalization allows active targeting using antibodies or ligands, improving therapeutic precision.

Polymeric nanoparticles also enhance drug stability and reduce enzymatic degradation in biological environments [4].

### 5.3 Dendrimers

Dendrimers are highly branched, tree-like macromolecules with a well-defined structure and multiple surface functional groups. Their unique architecture allows precise control over drug loading and release.

Dendrimers can encapsulate drugs within internal cavities or attach them to surface functional groups.

This dual-loading capability makes them highly versatile drug delivery systems.

They are widely studied in gene delivery, anticancer therapy, and diagnostic imaging.

**5.4 Micelles**

Polymeric micelles are self-assembling amphiphilic structures formed in aqueous environments. They consist of a hydrophobic core and hydrophilic shell, making them ideal for solubilizing poorly water-soluble drugs.

Micelles enhance drug stability, prolong circulation time, and enable passive tumor targeting through the enhanced permeability and retention (EPR) effect.

They are widely used in anticancer drug delivery and hydrophobic drug formulation [5].

**6. CONTROLLED AND SUSTAINED RELEASE DRUG DELIVERY SYSTEMS**

Controlled release systems are designed to release drugs at a predetermined rate to maintain consistent plasma drug concentrations over time. This minimizes fluctuations in drug levels, improving therapeutic efficacy and reducing side effects.

Sustained release formulations reduce dosing frequency, improving patient adherence and compliance. These systems are particularly beneficial in chronic diseases such as diabetes, hypertension, and cardiovascular disorders.

Common controlled release systems include:

- Matrix systems
- Reservoir systems
- Osmotic pump systems
- Diffusion-controlled systems

These systems rely on polymer matrices that regulate drug diffusion and degradation kinetics [6].

**7. TARGETED DRUG DELIVERY SYSTEMS**

Targeted drug delivery aims to deliver therapeutic agents directly to diseased tissues while minimizing exposure to healthy cells. This improves treatment efficacy and reduces systemic toxicity.

Targeting strategies include:

- Passive targeting (EPR effect)
- Active targeting (ligand-receptor binding)
- Physical targeting (magnetic or thermal guidance)

Active targeting uses ligands such as antibodies, peptides, or small molecules to bind specifically to receptors overexpressed on diseased cells.

This approach is widely used in cancer therapy, where selective targeting of tumor cells significantly improves treatment outcomes Table 01.

Table 01: Major Nanocarrier Systems in Pharmaceuticals

Nanocarrier Type	Structure	Key Advantage	Application
Liposomes	Phospholipid vesicles	Biocompatibility	Cancer therapy
Polymeric nanoparticl	Biodegradable	Controlled release	Gene/drug delivery

es	polymers		
Dendrimers	Branched polymers	High loading capacity	Diagnosis & therapy
Micelles	Amphiphilic aggregates	Solubilization of hydrophobic drugs	Oncology

**8. ADVANTAGES OF ADVANCED DRUG DELIVERY SYSTEMS**

Advanced drug delivery systems offer several important advantages over conventional formulations:

- Improved drug solubility and stability
- Enhanced bioavailability
- Target-specific delivery
- Reduced dosing frequency
- Lower systemic toxicity
- Improved patient compliance

These benefits collectively contribute to more efficient and safer therapeutic outcomes [7-8].

**9. STIMULI-RESPONSIVE DRUG DELIVERY SYSTEMS**

Stimuli-responsive (smart) drug delivery systems represent one of the most advanced developments in modern pharmaceuticals. These systems are designed to release therapeutic agents in response to specific internal or external stimuli, ensuring highly controlled and site-specific drug delivery.

Internal stimuli include pH, enzyme levels, redox conditions, and glucose concentration, while external stimuli include temperature, magnetic fields, ultrasound, and light. Among these, pH-responsive systems are widely studied for cancer therapy because tumor microenvironments are more acidic compared to normal tissues.

For example, pH-sensitive nanoparticles remain stable in physiological blood pH but release their drug payload in acidic tumor sites, improving therapeutic precision and reducing systemic toxicity.

Temperature-sensitive hydrogels are another important class of smart systems that undergo phase transitions at specific temperatures, enabling controlled drug release at target sites [9].

Table 02: Emerging Technologies in Pharmaceuticals

Technology	Application	Advantage
Stimuli-responsive systems	Targeted drug release	High precision
mRNA therapeutics	Vaccines & protein expression	Rapid development
Gene therapy	Genetic disorders	Curative potential
3D printing	Personalized medicine	Dose customization
AI in	Formulation	Faster

pharmaceutics	optimization	development
---------------	--------------	-------------

## 10. BIOPHARMACEUTICAL INNOVATIONS IN PHARMACEUTICS

Biopharmaceuticals have significantly expanded the scope of pharmaceuticals by introducing highly specific and effective therapeutic agents such as monoclonal antibodies, recombinant proteins, gene therapies, and nucleic acid-based drugs [10].

### 10.1 Monoclonal Antibodies

Monoclonal antibodies are highly specific biological molecules engineered to target disease-associated antigens. They are widely used in cancer immunotherapy, autoimmune diseases, and infectious diseases.

### 10.2 Gene Therapy

Gene therapy involves the delivery of genetic material into patient cells to correct defective genes or introduce therapeutic genes. Viral and non-viral vectors are used as delivery systems.

### 10.3 mRNA-Based Therapeutics

mRNA technology has gained global attention due to its success in vaccine development. It enables rapid protein expression in cells without altering the genome, making it a highly adaptable therapeutic platform.

These innovations have transformed pharmaceuticals into a highly personalized and precision-driven discipline.

## 11. 3D Printing in Pharmaceuticals

Three-dimensional (3D) printing technology has introduced a new era in pharmaceutical manufacturing. It allows the fabrication of customized dosage forms with precise control over drug release profiles, shape, and dosage strength.

3D-printed tablets can be designed for immediate, delayed, or controlled release based on patient-specific needs. This technology supports personalized medicine by enabling tailored drug formulations for individual patients.

It also reduces manufacturing waste and improves production efficiency in pharmaceutical industries [11].

## 12. ARTIFICIAL INTELLIGENCE IN PHARMACEUTICS

Artificial intelligence is increasingly being integrated into pharmaceuticals for formulation design, drug release prediction, and optimization of drug delivery systems.

Machine learning algorithms can analyze formulation parameters to predict dissolution rates, stability profiles, and bioavailability. AI also assists in selecting optimal excipients and predicting nanoparticle behavior in biological systems.

This integration significantly reduces experimental workload and accelerates pharmaceutical development processes [12].

## 13. CHALLENGES IN MODERN PHARMACEUTICS

Despite major advancements, several challenges still limit the widespread adoption of novel drug delivery systems:

- Complex and costly manufacturing processes
- Stability issues in biological environments
- Scale-up difficulties from laboratory to industrial production
- Regulatory approval challenges
- Potential toxicity of nanomaterials
- Limited long-term safety data

These challenges highlight the need for further research in formulation science, nanotoxicology, and regulatory frameworks [13-14].

## 14. FUTURE PERSPECTIVES

The future of pharmaceuticals is expected to be driven by personalized medicine, smart drug delivery systems, and integration of advanced computational technologies. Emerging trends include:

- AI-guided formulation design
- Fully biodegradable nanocarriers
- Organ-specific targeting systems
- Integration of biosensors with drug delivery
- Real-time drug release monitoring systems

The convergence of biotechnology, nanotechnology, and digital health will redefine pharmaceutical sciences and enable highly efficient, patient-centered therapies.

## 15. CONCLUSION

Pharmaceuticals has evolved significantly from conventional dosage forms to highly sophisticated drug delivery systems incorporating nanotechnology, biomaterials, and smart responsive technologies. These advancements have improved drug bioavailability, targeting efficiency, and patient compliance while reducing systemic toxicity. Innovations such as liposomes, polymeric nanoparticles, stimuli-responsive systems, biopharmaceuticals, and 3D printing have reshaped modern drug delivery science. Despite challenges in scalability, safety, and regulation, continuous research and technological integration are expected to overcome these barriers. The future of pharmaceuticals lies in personalized, intelligent, and highly precise drug delivery systems that ensure optimal therapeutic outcomes for patients.

## 16. FUNDING

Nil

## 17. ACKNOWLEDGEMENT

Not Declared.

## 18. CONFLICT OF INTEREST

Nil

**19. INFORMED CONSENT**

Not applicable

**20. ETHICAL STATEMENT**

Not Applicable.

**REFERENCES**

1. Olusanya TO, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. *Molecules*. 2018 Apr 14;23(4):907.
2. Webber MJ, Langer R. Drug delivery by supramolecular design. *Chemical Society Reviews*. 2017;46(21):6600-20.
3. Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. *Journal of the American Chemical Society*. 2016 Jan 27;138(3):704-17.
4. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. *Nature reviews cancer*. 2017 Jan;17(1):20-37.
5. Parvin S, Bindal P, Tiwari H, Chandrul KK. Intervention and Treatment of HIV/AIDS through Nanotechnology. *International Journal of Pharmacy & Life Sciences*. 2024 Jan 1;15(1).
6. Tran TT, Tran PH. Controlled release film forming systems in drug delivery: the potential for efficient drug delivery. *Pharmaceutics*. 2019 Jun 20;11(6):290.
7. Nunes D, Loureiro JA, Pereira MC. Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimer's drugs. *Pharmaceutics*. 2022 Oct 26;14(11):2296.
8. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG. Advances in drug delivery systems, challenges and future directions. *Heliyon*. 2023 Jun 1;9(6).
9. Thapa RK, Kim JO. Nanomedicine-based commercial formulations: current developments and future prospects. *Journal of Pharmaceutical Investigation*. 2023 Jan;53(1):19-33.
10. Shah S, Nene S, Rangaraj N, Raghuvanshi RS, Singh SB, Srivastava S. Bridging the gap: academia, industry and FDA convergence for nanomaterials. *Drug development and industrial pharmacy*. 2020 Nov 1;46(11):1735-46.
11. Khan FA. Nanocarriers-based products in the market, FDA approval, commercialization of nanocarriers, and global market. In *Nano drug delivery for cancer therapy: principles and practices* 2024 Jan 9 (pp. 137-148). Singapore: Springer Nature Singapore.
12. Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu ZX, Chen ZS, Hou K. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges. *Frontiers in oncology*. 2022 Mar 29;12:867655.
13. Fattahi F, Khoddami A, Avinc O. Poly (lactic acid) nanofibres as drug delivery systems: Opportunities and challenges. *Nanomedicine Research Journal*. 2019 Sep 1;4(3):130-40.
14. Chang, T.M.S., 2019. ARTIFICIAL CELL evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology. *Artificial cells, nanomedicine, and biotechnology*, 47(1), pp.997-1013.